ECTRIMS: Rituximab Beats MS Drugs in Swedish Registry Study (CME/CE)

(MedPage Today) -- Finds survival advantage for rituximab over fingolimod and natalizumab
Source: MedPage Today State Required CME - Category: Consumer Health News Source Type: news
More News: Gilenya | Health | Rituxan | Study | Tysabri